Matches in SemOpenAlex for { <https://semopenalex.org/work/W943306487> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W943306487 endingPage "7" @default.
- W943306487 startingPage "1225" @default.
- W943306487 abstract "Migraine is a headache condition found in significant frequency in the general population. One recent study has shown that riboflavin, Vitamin B2, is an effective prophylactic treatment for this headache condition. One subject in a recent study conducted by the Division of Forensic Toxicology, Armed Forces Institute of Pathology (AFIP) was taking 200 mg of riboflavin twice daily for the prevention of migraine headaches. When that subject's urine was tested using Abbott TDx drugs-of-abuse assays a number of tests resulted in a MX BKG error and all samples had BLK I values greater than those observed with normal urine specimens. The MX BKG error occurs when the BLK I value is greater than the upper limit determined by the manufacturer for a particular assay. High BLK I values may result if the specimen being analyzed contains a fluorophore that will compete with the fluorescein-labeled antibody used in the assay. This error serves as a notification that an interfering substance may be present and the assay is not performing according to manufacturer-specifications. Upon termination of riboflavin therapy the subject's BLK I values began to decrease within 60 h of the last 200 mg dose. A second subject began chronic riboflavin use to confirm this interferent effect. Elevated BLK I values resulted within 3 h of a single 200 mg dose and MX BKG errors occurred 1 h after a second 400 mg dose. No false negative results were noted with either subject (both subjects used butalbital and the first subject also used hydrocodone and diazepam during the study), suggesting that riboflavin is not an adulterant. Riboflavin use, however, does interfere with the TDx DAU assays and may result in quantitative values being determined which are of questionable validity in the face of an elevated BLK I value or may result in only an MX BKG error and no quantitative value reported. It is unclear if the interfering fluorophore is simply riboflavin itself or a combination of riboflavin and its metabolic products. Results obtained on urine samples collected from individuals using prophylactic riboflavin for migraine prevention and analyzed by TDx may be of questionable validity. Such samples may require analysis utilizing another immunoassay technique that does not employ a fluorescein-labeled antibody." @default.
- W943306487 created "2016-06-24" @default.
- W943306487 creator A5028163989 @default.
- W943306487 creator A5035959416 @default.
- W943306487 creator A5053253774 @default.
- W943306487 date "1998-11-01" @default.
- W943306487 modified "2023-09-23" @default.
- W943306487 title "Vitamin B2 interference with TDx drugs-of-abuse assays." @default.
- W943306487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9846401" @default.
- W943306487 hasPublicationYear "1998" @default.
- W943306487 type Work @default.
- W943306487 sameAs 943306487 @default.
- W943306487 citedByCount "5" @default.
- W943306487 countsByYear W9433064872012 @default.
- W943306487 countsByYear W9433064872015 @default.
- W943306487 crossrefType "journal-article" @default.
- W943306487 hasAuthorship W943306487A5028163989 @default.
- W943306487 hasAuthorship W943306487A5035959416 @default.
- W943306487 hasAuthorship W943306487A5053253774 @default.
- W943306487 hasConcept C126322002 @default.
- W943306487 hasConcept C141071460 @default.
- W943306487 hasConcept C185592680 @default.
- W943306487 hasConcept C2776155809 @default.
- W943306487 hasConcept C2776940978 @default.
- W943306487 hasConcept C2778541695 @default.
- W943306487 hasConcept C2780026642 @default.
- W943306487 hasConcept C2780966972 @default.
- W943306487 hasConcept C2908647359 @default.
- W943306487 hasConcept C33070731 @default.
- W943306487 hasConcept C55493867 @default.
- W943306487 hasConcept C71924100 @default.
- W943306487 hasConcept C86803240 @default.
- W943306487 hasConcept C98274493 @default.
- W943306487 hasConcept C99454951 @default.
- W943306487 hasConceptScore W943306487C126322002 @default.
- W943306487 hasConceptScore W943306487C141071460 @default.
- W943306487 hasConceptScore W943306487C185592680 @default.
- W943306487 hasConceptScore W943306487C2776155809 @default.
- W943306487 hasConceptScore W943306487C2776940978 @default.
- W943306487 hasConceptScore W943306487C2778541695 @default.
- W943306487 hasConceptScore W943306487C2780026642 @default.
- W943306487 hasConceptScore W943306487C2780966972 @default.
- W943306487 hasConceptScore W943306487C2908647359 @default.
- W943306487 hasConceptScore W943306487C33070731 @default.
- W943306487 hasConceptScore W943306487C55493867 @default.
- W943306487 hasConceptScore W943306487C71924100 @default.
- W943306487 hasConceptScore W943306487C86803240 @default.
- W943306487 hasConceptScore W943306487C98274493 @default.
- W943306487 hasConceptScore W943306487C99454951 @default.
- W943306487 hasIssue "6" @default.
- W943306487 hasLocation W9433064871 @default.
- W943306487 hasOpenAccess W943306487 @default.
- W943306487 hasPrimaryLocation W9433064871 @default.
- W943306487 hasRelatedWork W108807732 @default.
- W943306487 hasRelatedWork W1990717391 @default.
- W943306487 hasRelatedWork W2030796517 @default.
- W943306487 hasRelatedWork W2188361212 @default.
- W943306487 hasRelatedWork W2419101319 @default.
- W943306487 hasRelatedWork W27690950 @default.
- W943306487 hasRelatedWork W2899084033 @default.
- W943306487 hasRelatedWork W3156349056 @default.
- W943306487 hasRelatedWork W943306487 @default.
- W943306487 hasRelatedWork W2355614015 @default.
- W943306487 hasVolume "43" @default.
- W943306487 isParatext "false" @default.
- W943306487 isRetracted "false" @default.
- W943306487 magId "943306487" @default.
- W943306487 workType "article" @default.